HASBROUCK HEIGHTS, N.J., June 2, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced the dosing of the first patient in the Company's NX02-0017 multi-center, double-blind, placebo controlled Phase 3 U.S. clinical trial for NX-1207, the Company's investigational drug for the treatment of benign prostatic hyperplasia (BPH).
